FRANK MCCORMICK - 21 Feb 2023 Form 3 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/Brian Stephenson, as attorney-in-fact
Issuer symbol
BBIO
Transactions as of
21 Feb 2023
Net transactions value
$0
Form type
3
Filing time
28 Feb 2023, 20:52:00 UTC
Next filing
28 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBIO Common Stock 1,200,065 21 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBIO Stock Option (right to buy) 21 Feb 2023 Common Stock 265,463 $17.00 Direct F1
holding BBIO Stock Option (right to buy) 21 Feb 2023 Common Stock 10,549 $1.05 Direct
holding BBIO Stock Option (right to buy) 21 Feb 2023 Common Stock 18,566 $40.03 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 237,810 shares have vested to date. The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such date.

Remarks:

Exhibit 24 - Power of Attorney